MGEN - Miragen Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.7300
-0.1000 (-3.53%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.8300
Open2.8200
Bid2.7300 x 1800
Ask2.7400 x 1300
Day's Range2.7200 - 2.8200
52 Week Range2.2000 - 7.9400
Volume170,948
Avg. Volume188,587
Market Cap84.415M
Beta (3Y Monthly)1.90
PE Ratio (TTM)N/A
EPS (TTM)-1.1050
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.10
Trade prices are not sourced from all markets
  • GuruFocus.comlast month

    Miragen Therapeutics Inc (MGEN) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Miragen Therapeutics Inc is a clinical-stage biopharmaceutical company which engaged in discovering and developing proprietary RNA (Ribonucleic acid)-targeted therapeutics. Miragen Therapeutics Inc had annual average EBITDA growth of 4.00% over the past five years. Warning! GuruFocus has detected 3 Warning Signs with MGEN.

  • Signal Genetics, Inc. (MGEN) Reports Q4 Loss, Misses Revenue Estimates
    Zackslast month

    Signal Genetics, Inc. (MGEN) Reports Q4 Loss, Misses Revenue Estimates

    Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of -6.45% and -69.15%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswirelast month

    miRagen Announces Fourth Quarter and Full Year 2018 Financial Results and Provides 2019 Outlook

    BOULDER, Colo., March 13, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today reported financial and operating results for the fourth quarter and full-year ended December 31, 2018. “We are encouraged by the advances our team has made in the development of microRNA targeted therapies in 2018 and pleased to begin 2019 with three clinical stage product candidates being evaluated in five clinical trials for the potential to treat patients who suffer from a variety of diseases with high unmet medical need.” said William S. Marshall, Ph.D., President and Chief Executive Officer of miRagen Therapeutics. “In addition to the release of encouraging clinical data for cobomarsen in cutaneous T-cell lymphoma (CTCL), we have also seen exciting preliminary clinical activity for cobomarsen in other blood cancers and have also advanced the development of remlarsen into a Phase 2 clinical trial in cutaneous fibrosis.

  • GlobeNewswirelast month

    miRagen Therapeutics to Present a Corporate Overview at the 29th Annual Oppenheimer & Co. Healthcare Conference

    BOULDER, Colo., March 06, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that William S. Marshall, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the Oppenheimer & Co. 29th Annual Healthcare Conference, taking place March 19-20 in New York City.

  • GlobeNewswire2 months ago

    miRagen Therapeutics to Report Fourth Quarter and Fiscal 2018 Financial Results and Host a Conference Call on March 13th

    BOULDER, Colo., Feb. 20, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will host a conference call on Wednesday, March 13, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and fiscal year ended December 31, 2018. The call will also be webcast and can be accessed from the Investors and Media section of the Company’s website at www.miragen.com.  A replay of this conference call will be available on miRagen’s website approximately one hour after the event.

  • Colorado biotech firms are developing drugs to fight cancer, help children and cut down on excessive sweating
    American City Business Journals3 months ago

    Colorado biotech firms are developing drugs to fight cancer, help children and cut down on excessive sweating

    When it comes to top biotech clusters in the country, Colorado is in the conversation, but has a way to go to be mentioned in the same breath as California and Massachusetts, where a majority of investor money goes into drug development. “I’d say it’s really on fire right now,” said Frank Segrave, CEO of Silvergate Pharmaceuticals. “Part of that is all the really good collaboration between the state, the academic institutions and the business community, but it’s also the economy here, the quality of life that’s really building up the industry here.” Home to about 720 bioscience firms, a majority of which are in a pre-revenue stage, the industry here is making a concentrated push to attract more investment so that more companies can complete research and bring drugs and medical devices to market.

  • GlobeNewswire3 months ago

    miRagen Announces New Clinical Data in Patients With Three Different Types of Blood Cancers Treated With Cobomarsen

    50% of cutaneous T-cell lymphoma patients treated with 300mg IV infusion achieved objective response lasting for greater than four months (ORR4)Evidence of disease stabilization.

  • GlobeNewswire4 months ago

    miRagen Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult T-Cell Leukemia/Lymphoma and Cutaneous T-Cell Lymphoma at the 11th Annual T-Cell Lymphoma Forum

    BOULDER, Colo., Dec. 20, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it will present new data from its Phase 1 trial of cobomarsen in HTLV-1 associated adult T-cell leukemia/lymphoma (ATLL) as well as its Phase 1 trial of cobomarsen in patients with mycosis fungoides, the most common form of cutaneous T-cell (CTCL) at the 11th Annual T-Cell Lymphoma Forum, which is being held in La Jolla, CA, from January 10th-12th.

  • Hedge Funds Are Crazy About Miragen Therapeutics, Inc. (MGEN)
    Insider Monkey4 months ago

    Hedge Funds Are Crazy About Miragen Therapeutics, Inc. (MGEN)

    The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review […]

  • GlobeNewswire4 months ago

    miRagen Therapeutics Announces Board of Director Evolution and Appointment of New Chairman

    BOULDER, Colo., Dec. 05, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the appointment of Jeff Hatfield, a Director since 2017, as Chairman of the Board of Directors. Mr. Hatfield succeeds Bruce Booth, DPhil., who is stepping down in order to focus on making new investments in the Atlas Venture portfolio.  Additionally, current Director Arlene Morris will replace Dr. Booth on the audit committee. The Board will be comprised of seven directors, including six non-executive directors.

  • GlobeNewswire5 months ago

    miRagen Therapeutics Announces Final Safety, Biodistribution and Clinical Efficacy Data From Phase 1 Cobomarsen Clinical Trial in Patients With Mycosis Fungoides

    “We are excited to present final data from our Phase 1 cobomarsen clinical trial, which continue to show that cobomarsen is safe and well-tolerated, has relevant biological and clinical activity in patients and has the potential to impact the quality of life for MF patients,” stated miRagen Executive Vice President, R&D, Paul Rubin. The Phase 1 clinical trial investigated the safety, tolerability, PK, PD and efficacy of cobomarsen in a total of 43 MF patients.  Cobomarsen was initially administered via intratumoral injection (75 mg/dose), and then via systemic administration by subcutaneous (SC), intravenous (IV) bolus or IV infusion, at 300, 600 or 900 mg/dose with loading doses in the first week followed by weekly maintenance dosing.

  • Signal Genetics, Inc. (MGEN) Reports Q3 Loss, Misses Revenue Estimates
    Zacks5 months ago

    Signal Genetics, Inc. (MGEN) Reports Q3 Loss, Misses Revenue Estimates

    Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of 9.38% and -50.13%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire5 months ago

    miRagen Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update

    Continued advancements of three clinical stage microRNA-targeted product candidates currently being evaluated for multiple potential indications in four clinical trialsGlobal.

  • GlobeNewswire6 months ago

    Miragen Therapeutics to Present New Cobomarsen Phase 1 Clinical Trial Data at the 2018 American Society of Hematology Annual Meeting

    BOULDER, Colo., Nov. 01, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that new data from its Phase 1 trial of cobomarsen, an inhibitor of miR-155, in patients with mycosis fungoides, the most common form of cutaneous T cell lymphoma, will be presented at the 60th American Society of Hematology (ASH) Annual Meeting, which is being held in San Diego, CA, from December 1st – 4th.

  • ACCESSWIRE8 months ago

    Miragen Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Miragen Therapeutics, Inc. (NASDAQ: MGEN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern ...